Exosens Reports Q3 2026 Financial Results and Confirms Full-Year Outlook

Exosens reported Q3 2026 revenue growth of 23.5%, with nine-month revenue rising 18% year over year to €386.9 million. It confirmed full-year guidance of approximately 20% revenue growth, to €558 million–€570 million, and adjusted EBITDA of €186 million–€192 million. Nine-month adjusted gross margin was €194.9 million, while the margin rate fell 85 basis points to 50.4%, which the company attributed to product mix and higher personnel costs as it deployed a new U.S. manufacturing facility. Management cited robust demand and a faster-than-expected production ramp-up as drivers of growth.